15.95
-0.17 (-1.05%)
| Previous Close | 16.12 |
| Open | 16.35 |
| Volume | 96,578 |
| Avg. Volume (3M) | 22,062 |
| Market Cap | 21,121,760 |
| Price / Sales | 1.02 |
| Price / Book | 1.20 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2024 - 18 Nov 2024 |
| Profit Margin | -114.11% |
| Operating Margin (TTM) | -56.90% |
| Diluted EPS (TTM) | -19.21 |
| Quarterly Revenue Growth (YOY) | -97.30% |
| Current Ratio (MRQ) | 3.95 |
| Operating Cash Flow (TTM) | -37.87 M |
| Levered Free Cash Flow (TTM) | -25.49 M |
| Return on Assets (TTM) | -13.18% |
| Return on Equity (TTM) | -80.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Pieris Pharmaceuticals, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 0.0 |
| Average | -0.75 |
|
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.07% |
| % Held by Institutions | 47.71% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |